Khiron Life Sciences Corp. (OTCPK: KHRN.F)
Health Care · Pharmaceuticals · CO
$0.00
-90.00% today · 0.0% 1Y
Khiron Life Sciences Corp. (OTCPK: KHRN.F) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $232.00.
Over the last twelve months the share price has gained 0.0%, trading between 0.00 and 0.00.
Tweenvest scores Khiron Life Sciences Corp. across four factors: quality 18/100, value 44/100. Its strongest factor is value.
KHRN.F price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $232.00
- Revenue (TTM)
- $11.75M
- P/E
- —
- EPS
- -0.16
- Dividend yield
- —
- Beta (5Y)
- 21.05
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 232.41M
- Employees
- —
- Next earnings
- —
About Khiron Life Sciences Corp.
Khiron Life Sciences Corp. operates as an integrated medical and cannabis company in Latin America and Europe. It operates through Health Services, Medical Cannabis Products, and Wellbeing Products segments. The company focuses on the cultivation, production, distribution, and export of tetrahydrocannabinol and cannabidiol (CBD) medical cannabis. It also operates a network of health centers and satellite clinics under the ILANS and Zerenia brands; develops CBD-based cosmeceutical products under the Kuida brand name; and operates Zerenia clinic in Medellin and Peru. Khiron Life Sciences Corp. was incorporated in 2012 and is headquartered in Vancouver, Canada.
- ISIN
- CA49374L3065
- Listed since
- May 24, 2018
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,237.51 | -1.43% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $272.29 | +0.76% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $150.48 | -1.36% |
| Roche Holding AGSWX: ROP | $373.91B | CHF369.10 | -1.73% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £120.32 | -1.70% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $27.89 | -0.64% |
Figures last refreshed Aug 18, 2026.